Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Camizestrant in combination with capivasertib for women with ER-positive, HER2-negative advanced breast cancer: results from SERENA-1.

ESMO open·2026
Same author

Gestational breast cancer: distinctive molecular and clinico-epidemiological features.

Journal of mammary gland biology and neoplasia·2024
Same author

ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Lenvatinib plus pembrolizumab a new effective combination of targeted agents.

ESMO open·2023
Same author

Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER).

European journal of cancer (Oxford, England : 1990)·2021
Same author

Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer.

ESMO open·2021

Related Experiment Video

Updated: Apr 30, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K

Subcutaneous trastuzumab: drug development and current position.

P Martín Martorell1, B Bermejo de Las Heras, J A Pérez-Fidalgo

  • 1Hematology and Medical Oncology Department, Hospital Clínico Universitario de Valencia, Avda. Blasco Ibáñez 17, 46010, Valencia, Spain, paloma_martin@comv.es.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|April 30, 2014
PubMed
Summary

The advent of anti-HER2 drugs has improved outcomes for HER2-positive breast cancer. A new subcutaneous formulation of trastuzumab offers a more convenient treatment option, addressing logistical challenges.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

6.5K
High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

3.0K

Related Experiment Videos

Last Updated: Apr 30, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

6.5K
High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

3.0K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • HER2-positive breast cancer accounts for 15% of cases and historically had a poor prognosis.
  • Anti-HER2 drugs have significantly improved survival and disease control.

Purpose of the Study:

  • To review the drug development of trastuzumab.
  • To discuss the current evidence on the use of a new subcutaneous formulation of trastuzumab.

Main Methods:

  • Review of existing literature on trastuzumab drug development.
  • Analysis of current clinical evidence for subcutaneous trastuzumab.

Main Results:

  • HER2-targeted therapy has transformed the prognosis of HER2-positive breast cancer.
  • Trastuzumab, while effective, presents prolonged treatment duration challenges.
  • A subcutaneous formulation of trastuzumab has been developed to improve convenience.

Conclusions:

  • Subcutaneous trastuzumab represents a significant advancement in managing HER2-positive breast cancer.
  • This formulation addresses the time and resource challenges associated with prolonged intravenous trastuzumab treatment.